This week, we chat with Simon Mølgaard, co-founder and chief executive officer of Teitur Trophics about results from its Parkinson’s disease trial, and have a conversation with Jordi Fàbrega, co-founder and CEO of CONNECTA Therapeutics, and Josep Prous, the company’s co-founder and chief scientific officer, about Fragile X syndrome.
Times:
03:15 Teitur Trophics
14:03 CONNECTA Therapeutics
Teitur Trophics
Teitur Trophics recently announced successful results from its phase I clinical trial of its lead asset TT-P34 in healthy volunteers and patients with early-stage Parkinson’s disease (PD).
The positive results support plans to initiate a phase II trial in PD patients in 2027, which will be designed to explore the therapeutic benefit and disease modifying potential of TT-P34.
TT-P34 is a first-in-class therapy that, through a dual mechanism of action, improves both mitochondrial and lysosomal function. Its unique mode of action, targeting a critical pathway that underpins multiple aspects of pathology, means TT-P34 also has potential as a disease-modifying drug for other neurodegenerative conditions including frontotemporal dementia and Huntington’s disease.
CONNECTA
CONNECTA Therapeutics is a Barcelona-based clinical-stage biotech company developing first-in-class neuroplasticity modulators for central nervous system (CNS) disorders.
The company recently announced a €3.1m financing to support the advancement of CTH120, CONNECTA’s lead programme for Fragile X syndrome (FXS), including completion of the ongoing phase IIa clinical trial in adult males with FXS, with topline data expected in mid-2027.
The financing comes at a key stage for the company as it works to address the underlying neurobiology of FXS, a rare and currently untreatable neurodevelopmental disorder, through its differentiated neuroplasticity modulation platform.
To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com